Fluoropyrimidine resistance in colon cancer

References

• Bertino JR. Kamofsky Memorial Lecture: ode to methotrexate. j Clin. Oncol 11, 5–14(1993).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Bertino JR. Drug resistance in colon cancer. Semin. Oncol 26, 606–611 (1999).
   PubMed Web of Science ®Google Scholar
• Boring CC, Squires TS, Tong T Cancer statistics 1993. 43, 7–26 (1993).
   Google Scholar
• Cohen AM, Shank B, Friedman MA. Colorectal cancer. In: Cancer Principles and Practice of Oncology Devita VT, Hellman S, Rosenberg SA (Eds), Lippincott-Raven, Philadelphia, PA, USA, 895–964, (1989).
   Google Scholar
• Goker E, Gorlick R, Bertino JR. Resistance mechanisms to antimetabolites. In: Drug Resistance in the Treatment of Cancer Pinedo HM, Giaccone G (Eds), Cambridge University Press, Cambridge, MA, USA, 1-13(1998).
   Google Scholar
• Grem JL. Fluorinated pyrimidines. In: Cancer Chemotherapy and Biotherapy Chabner BA, Longo DL (Eds), Lippincott-Raven, Philadelphia, PA, USA, 180–224 (1996).
   Google Scholar
• Will CL, Dolnick BJ. 5-Fluorouracil inhibits dihydrofolate reductase precursormRNA processing and/or nuclear mRNAstability in methotrexate-resistant KB cells.Biol. Chem. 264, 21413–21421 (1989).
   Google Scholar
• •5-Fluorouracil treatment increases the levels of precursor mRNA relative to mRNA levels suggesting the drug affects RNA processing or stability.
   Google Scholar
• Kinsella AR, Smith D, Pickard M et al. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br. Cancer75, 935–945 (1997).
   Google Scholar
• Sobrero, AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer — a tale of two drugs: implications for biochemical modulation. Clin. Oncol 15, 368–381 (1997).
   Google Scholar
• ••Discussed that 5-FU mechanisms of actionand resistance depends on whether it is given as a bolus or a continuous infusion.
   Google Scholar
• Jenh CH, Geyer PK, Baskin F et al. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mal Pharmacol 28, 80–85 (1985).
   PubMed Web of Science ®Google Scholar
• Copur S, Aiba K, Drake JC et al. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem. Pharmacol 49,1419–1426 (1995).
   Google Scholar
• Clark JL, Berger SH, Mittelman A et al Thymidylate synthase overproduction gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat. Rep. 71, 261–265 (1987).
   PubMedGoogle Scholar
• Lenz HJ, Leichman CG, Danenberg KID et al Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival." Clin. Dna. 14, 176–182 (1996).
   Google Scholar
• Leichman L, Lenz HJ, Leichman CG et al Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial. Eur. J. Cancer 31A, 1306–1310 (1995).
   Google Scholar
• Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55, 1407–1412 (1995).
   PubMed Web of Science ®Google Scholar
• •One of several early and influential studies that demonstrated both low TS mRNA and protein expression were associated with response to 5-FU chemotherapy.
   Google Scholar
• Johnston PG, Fisher ER, Rockette HE et al The role of thymidylate synythase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. Clin. Oncol 12, 2640–2647 (1994).
   Web of Science ®Google Scholar
• Yamachika T, Nakanishi H, Inada K et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance. Cancer 82, 70–77 (1998).
   PubMed Web of Science ®Google Scholar
• Leichman L, Lenz HJ, Leichman CG et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal response and resistance to protracted infusion of fluorouracil and weekly leucovorin. j Clin. Dried 15, 3223–3229 (1997).
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Hayashi K, Salonga D et al p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res. 4, 1243–1250 (1998).
   Google Scholar
• Aschele C, Debernarclis D, Casazza S et al Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. Clin. Oncol 17, 1760–1767 (1999).
   Google Scholar
• Gorlick R, Metzger R, Danenberg KD et al Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared to hepatic metastases of colorectal adenocarcinoma. j Clin. Oncol 16, 1465–1469 (1998).
   PubMed Web of Science ®Google Scholar
• •Study demonstrated that the pulmonary metastases of colorectal cancer have higher levels of TS than hepatic metastases explaining their lack of response to 5-FU.
   Google Scholar
• Cascinu S, Aschele C, Barni S et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the sites of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin. Cancer Res. 5, 1996–1999 (1999).
   Google Scholar
• Baneijee D, Gorlick R, Liefshitz A et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 60, 2365–2367 (2000).
   PubMedGoogle Scholar
• •Suggests that the E2F-1 transcription factor may be regulating the levels of TS expression in colon cancer.
   Google Scholar
• Chu E, Voeller D, Koeller DM et al Identification of an RNA binding site for human thymidylate synthase. Proc. Natl Acad. Sci. USA 90, 517–521 (1993).
   PubMed Web of Science ®Google Scholar
• Kitchens ME, Forsthoefel AM, Rafique Z, Spencer HT, Berger FG. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J. Biol. Chem. 274, 12544–12547 (1999).
   Google Scholar
• ••Suggests that 5-FU modulates IS proteinlevels in the absence of transcription by altering protein stability rather than through regulation of translation, which had been believed previously.
   Google Scholar
• Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics 1, 65–70 (2001).
   Google Scholar
• •A polymorphism exists in the IS promoter having either double or triple tandem repeats and it is associated with the toxicity and response patients have following 5-FU chemotherapy.
   Google Scholar
• Ju J-F, Baneijee D, Lenz H-J et al. Restoration of wild type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin. Cancer Res. 4, 1315–1322 (1998).
   Google Scholar
• Lowe SW Bodis S, McClatchey A et al p53 status and the efficacy of cancer therapy in vivo. Science 266, 807–810 (1994).
   PubMedGoogle Scholar
• Livingstone LR, White A, Sprouse J et al Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Ce1170, 923–935 (1992).
   Google Scholar
• Yin Y, Tainsky MA, Bischoff FZ. Wild type p53 restores cell cycle control and inhibits gene amplification in cells without mutant p53 alleles. Ce1170, 937–948 (1992).
   Google Scholar
• Goker E, Waltham M, Kheradpour A et al Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia and is correlated with p53 gene mutations. Blood 86, 677–684 (1995).
   PubMed Web of Science ®Google Scholar
• Pritchard DM, Watson AJM, Potten CS et al. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl Acad. Sci. USA 94, 1795–1799 (1997).
   Google Scholar
• Harwood FG, Frazier MW Krajewski S et al. Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells. Oncogene 12, 2057-2067 (1996).
   Google Scholar
• O'Connor PM, Jackman J, Bae I et al Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285–4300 (1997).
   PubMed Web of Science ®Google Scholar
• Kastrinakis WV, Ramchurren N, Rieger KM et al Increased incidence of p53 mutations is associated with hepatic metastases in colorectal neoplastic progression. Oncogenell, 647–652 (1995).
   Google Scholar
• Flamini G, Curigliano G, Ratto C et al. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur. Cancer32A, 802–806 (1996).
   Google Scholar
• Belluco C, Guillem JG, Kemeny N et al. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. j Clin. Oncol 14, 2696–2701 (1996).
   Google Scholar
• •Demonstrates that the presence of p53 alterations determined imrnunohistochemically is a strong predictor of survival in patients with colorectal cancer who have hepatic metastases.
   Google Scholar
• Cascinu S, Catalano V, Aschele C et al. Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann. Oncol 11, 1053–1056 (2000).
   Google Scholar
• •Demonstrated that p53 status measured by imrnunohistochemistry did not correlate with response to 5-FU in patients with advanced colorectal cancer. This contradicts the findings of the prior cited studies.
   Google Scholar
• Nevins JR. E2E A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258, 424–429 (1992).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl. I Med. 335, 1041–1048 (1996).
   PubMed Web of Science ®Google Scholar
• Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245–2262 (1998).
   PubMed Web of Science ®Google Scholar
• Muller H, Helm n K. The E2F transcription factors: key regulators of cell proliferation. Biochim. Biophys. Acta 1470, M1—M12 (2000).
   Google Scholar
• DeGregori J, Kowalik U, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G15-regulatory genes. Mal Cell. Biol. 15, 4215–4224 (1995).
   Google Scholar
• Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao S-C, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res. 58, 4292–4296 (1998).
   Google Scholar
• ••Demonstrates that elevated levels of E2F-1result in 5-FU resistance through increased IS expression as well as collateral sensitivity to irinotecan.
   Google Scholar
• Kasahara M, Takahashi Y, Nagata U et al Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer. Clin. Cancer Res. 6, 2707–2711 (2000).
   Google Scholar
• Zhang SY, Shao S-C, Johnson DG, Klein-Szanto AJP E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res. 60, 5972–5976 (2000).
   PubMed Web of Science ®Google Scholar
• Mulkins MA, Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res. 42, 965–973 (1982).
   PubMed Web of Science ®Google Scholar
• Wang F-S, Aschele C, Sobrero A et al Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res. 53, 3677–3680 (1993).
   PubMedGoogle Scholar
• Sobrero AF, Moir RD, Bertino JR et al Defective facilitated diffusion of nucleotides, a primary mechanism of resistance to 5-fluoro-2 --deoxyuridine in the HCT-8 human carcinoma. Cancer Res. 45, 3155–3160 (1985).
   PubMed Web of Science ®Google Scholar
• Aschele C, Sobrero A, Faderan M, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52, 1855–1864 (1992).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that different 5-FU treatment regimens can result in different patterns of resistance including alterations in activation pathway enzymes, such as UMPK.
   Google Scholar
• Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem. Phatmacol 49, 599–605 (1995).
   Google Scholar
• Etienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.j Clin. Oncol 13, 1663–1670 (1995).
   PubMed Web of Science ®Google Scholar
• Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. j Clin. Oncol 12, 2239–2242 (1994).
   PubMed Web of Science ®Google Scholar
• Metzger R, Danenberg K, Leichman CG et al High basal level gene expression of thymidine phosphorylase (platelet derived endothelial growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil. Clin. Cancer Res. 4, 2371–2376 (1998).
   Google Scholar
• Salonga D, Danenberg KD, Johnson M et al Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Gun. Cancer Res. 6, 1322–1327 (2000). Demonstrated that the level of expression of all three genes predicted response and they were independent of each other. Patients with low expression of all three genes had an increased survival.
   Google Scholar
• Conti JA, Kemeny NE, Saltz LB et al Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol 14, 709–715 (1996).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW et al Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur Cancer35, 54–59 (1999).
   PubMed Web of Science ®Google Scholar
• •In patients with colorectal cancer and documented progression of disease while on 5-FU, hinotecan achieved a response rate of 13.7%.
   Google Scholar
• Saltz L, Danenberg K, Paty P et al High thymidylate synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol 17, 281 (1998).
   Google Scholar
• Li M-X, Banerjee D, Zhao S-C et al development of a retroviral construct containing a human mutated dhfr cDNA for hematopoietic stem cell transduction. Blood33, 3403–3408 (1994).
   Google Scholar
• Banerjee D, Zhao S-C, Mineishi S, Bertino JR. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Hum. Gene Ther. 8, 903–909 (1997).
   Google Scholar
• Flasshove M, Banerjee D, Mineishi S, Li M-X, Bertino JR, Moore MAS. Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85, 566–574 (1995).
   Google Scholar